Seelos Therapeutics, Inc. (SEELQ) — Cash Flow-to-Debt Ratio
Seelos Therapeutics, Inc. (SEELQ) has a Cash Flow-to-Debt Ratio of -0.03x as of June 2024, meaning its operating cash flow of $-972.00K could theoretically repay 0% of its total liabilities ($30.51 Million) in one year. See SEELQ FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seelos Therapeutics, Inc. Cash Flow-to-Debt Ratio (2020–2023)
Historical debt coverage capacity for Seelos Therapeutics, Inc. across 4 annual periods. For the full cash flow conversion analysis, see SEELQ cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Seelos Therapeutics, Inc. (2020–2023)
Year-by-year debt coverage analysis for Seelos Therapeutics, Inc.. Check SEELQ cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -0.61x | $-23.91 Million | $38.93 Million | ▲ +66.7% |
| 2022 | -1.85x | $-61.60 Million | $33.36 Million | ▲ +1.3% |
| 2021 | -1.87x | $-48.99 Million | $26.18 Million | ▼ -33.5% |
| 2020 | -1.40x | $-20.91 Million | $14.92 Million | — |